Fortis Healthcare Q1 FY27: Revenue up 17.5% to ₹2,545 Cr, PAT at ₹263 Cr
Fortis Healthcare reported Q1 FY27 consolidated revenue of ₹2,545 Cr, up 17.5%. PAT was ₹263 Cr. Hospital revenue grew 19% to ₹2,187 Cr, and diagnostics revenue rose 10.2% to ₹407 Cr. The company is investing in new facilities and technology, including a proton therapy unit. A broad-based ESOP scheme was approved for doctors and senior staff.
The results show healthy growth and strategic investments, which are positive for the company's future performance. However, the impact is moderate as there are no groundbreaking announcements or significant financial changes that would drastically alter the company's valuation in the short term.
The company reported strong revenue growth in both its hospital and diagnostics segments, along with an increase in profit after tax. Expansion plans and investments in technology indicate a positive outlook.
Fortis Healthcare Limited announced its financial results for the first quarter of FY27, reporting a consolidated revenue of ₹2,545 crore, a 17.5% increase compared to the same period last year. The hospital business saw a revenue growth of 19% to ₹2,187 crore, while the diagnostic business gross revenue grew by 10.2% to ₹407 crore.
Consolidated operating EBITDA increased by 15.8% to ₹568 crore, with a margin of 22.3%. The hospital business reported an operating EBITDA of ₹471 crore (21.5% margin), and the diagnostic business's operating EBITDA margin improved to 23.9%. The consolidated profit after tax before exceptional items for the quarter rose by approximately 4% to ₹263 crore.
The company's net debt stood at ₹2,233 crore as of June 30, 2026, with a net debt-to-EBITDA ratio of 1.01x. Hospital occupancy remained steady at 69%, with occupied beds increasing by 17% to 3,418. Key specialties like renal sciences, neurosciences, and orthopedics showed significant revenue growth. Fortis also announced plans for a new greenfield hospital in Cuttack and investments in advanced robotic capabilities, including a proton facility at its Gurgaon hospital.
Agilus Diagnostics reported gross revenue of ₹407 crore, a 10.2% year-on-year growth, with operating EBITDA margins improving to 23.9%. The B2C to B2B revenue mix shifted to 53:47. The company processed approximately 10.5 million tests and added over 200 customer touchpoints during the quarter. Fortis Healthcare is also implementing a broad-based ESOP scheme for doctors and senior staff to align interests and reward contributions.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.